Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines

Vaccine

Volumn 18, Issue 19, 2000, Pages 2015-2022

  Chen, Chien Hung ^a,b   Wang, Tian Li ^a   Hung, Chien Fu ^a   Pardoll, Drew M ^a   Wu, T C ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

DNA vaccine; HPV 16; Vaccinia

Indexed keywords

CD8 ANTIGEN; CHIMERIC PROTEIN; DNA VACCINE; MEMBRANE PROTEIN; RECOMBINANT VACCINE; VACCINIA VACCINE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTER; GENE CONSTRUCT; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR IMMUNITY; VACCINATION; VACCINE PRODUCTION;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, CD; ANTIGENS, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; IMMUNIZATION, SECONDARY; LYSOSOME-ASSOCIATED MEMBRANE GLYCOPROTEINS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VACCINES, DNA; VACCINIA VIRUS; VIRAL VACCINES;

EID: 0034003977     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00528-9     Document Type: Article

References (26)

1. Tomatis L. Cancer, cause, occurrence and control. 1990;World Heath Organization, International Agency for Research on Cancer, Lyon.
2. Bosch F.X., Manos M.M., Munoz N., et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J. Natl Cancer Inst. 87:1995;796-802.
3. Wu T.C. Immunology of the human papilloma virus in relation to cancer. Curr. Opin. Immunol. 6:1994;746-754.
4. Lin K.-Y., Guarnieri F.G., Staveley-O'Carroll K.F., et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 56:1996;21-26.
5. Ji H., Chang E.Y., Lin K.Y., Kurman R.J., Pardoll D.M., Wu T.C. Antigen-specific immunotherapy for murine lung metastatic tumors expressing human papillomavirus type 16 E7 oncoprotein. Int. J. Cancer. 78:1998;41-45.
6. Ji H., Wang T.L., Chen C.H., et al. Targeting HPV-16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine HPV-16 E7-expressing tumors. Human Gene Therapy. 10:(17):1999;2727-2740.
7. Chen CH, Ji H, Suh KW, Choti MA, Pardoll DM, Wu TC. Gene gun-mediated DNA vaccination induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the liver and lungs Gene Therapy (in press).
8. Hanke T., Neumann V.C., Blanchard T.J., et al. Effective induction of HIV-specific CTL by multi-epitope using gene gun in a combined vaccination regime. Vaccine. 17:1999;589-596.
9. + T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med. 4:1998;397-402.
10. Sedegah M., Jones T.R., Kaur M., et al. Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. Proc. Natl Acad. Sci. USA. 95:1998;7648-7653.
11. Hanke T., Blanchard T.J., Schneider J., et al. Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime. Vaccine. 16:1998;439-445.
12. Kent S.J., Zhao A., Best S.J., Chandler J.D., Boyle D.B., Ramshaw I.A. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. J. Virol. 72:1998;10180-10188.
13. Wu T.C., Guarnieri F.G., Staveley O.C.K.F., et al. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc. Natl Acad. Sci. USA. 92:1995;11671-11675.
14. + T cells using an ELISPOT assay. J. Immunol. Methods. 181:1995;45-54.
15. Murali-Krishna K., Altman J.D., Suresh M., et al. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity. 8:1998;177-187.
16. Feltkamp M.C., Smits H.L., Vierboom M.P., et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur. J. Immunol. 23:1993;2242-2249.
17. McCutcheon M., Wehner N., Wensky A., et al. A sensitive ELISPOT assay to detect low-frequency human T lymphocytes. J. Immunol. Methods. 210:1997;149-166.
18. Tindle R.W., Fernando G.J., Sterling J.C., Frazer I.H. A "public" T-helper epitope of the E7 transforming protein of human papillomavirus 16 provides cognate help for several E7 B-cell epitopes from cervical cancer-associated human papillomavirus genotypes. Proc. Natl Acad. Sci. USA. 88:1991;5887-5891.
19. Hanke T., Samuel R.V., Blanchard T.J., et al. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J. Virol. 73:1999;7524-7532.
20. Hota-Mitchell S., Clarke M.W., Podesta R.B., Dekaban G.A. Recombinant vaccinia viruses and gene gun vectors expressing the large subunit of Schistosoma mansoni calpain used in a murine immunization-challenge model. Vaccine. 17:1999;1338-1354.
21. Hodge J.W., McLaughlin J.P., Kantor J.A., Schlom J. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses. Vaccine. 15:1997;759-768.
22. Belyakov I.M., Moss B., Strober W., Berzofsky J.A. Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. Proc. Natl Acad. Sci. USA. 96:1999;4512-4517.
23. Gilbert S.C., Schneider J., Plebanski M., et al. Ty virus-like particles, DNA vaccines and modified vaccinia virus Ankara; comparisons and combinations. Biol. Chem. 380:1999;299-303.
24. + T cell response to HIV-1 env by combined immunization with influenza and vaccinia virus recombinants. Vaccine. 17:1999;887-892.
25. Fuller D.H., Corb M.M., Barnett S., Steimer K., Haynes J.R. Enhancement of immunodeficiency virus-specific immune responses in DNA-immunized rhesus macaques. Vaccine. 15:1997;924-926.
26. Letvin N.L., Montefiori D.C., Yasutomi Y., et al. Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. Proc. Natl Acad. Sci. USA. 94:1997;9378-9383.